414 related articles for article (PubMed ID: 31009585)
21. Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease.
Liu H; Sridhar VS; Boulet J; Dharia A; Khan A; Lawler PR; Cherney DZI
Metabolism; 2022 Jan; 126():154918. PubMed ID: 34699838
[TBL] [Abstract][Full Text] [Related]
22. The landscape of diabetic kidney disease transformed.
Tuttle KR
Nat Rev Nephrol; 2020 Feb; 16(2):67-68. PubMed ID: 31831876
[No Abstract] [Full Text] [Related]
23. Protection of the kidney with sodium-glucose cotransporter 2 inhibitors: potential mechanisms raised by the large-scaled randomized control trials.
Kuriyama S
Clin Exp Nephrol; 2019 Mar; 23(3):304-312. PubMed ID: 30478731
[TBL] [Abstract][Full Text] [Related]
24. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.
Packer M; Anker SD; Butler J; Filippatos G; Zannad F
JAMA Cardiol; 2017 Sep; 2(9):1025-1029. PubMed ID: 28768320
[TBL] [Abstract][Full Text] [Related]
25. Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease.
Maruyama T; Takashima H; Oguma H; Nakamura Y; Ohno M; Utsunomiya K; Furukawa T; Tei R; Abe M
Diabetes Technol Ther; 2019 Dec; 21(12):713-720. PubMed ID: 31385724
[No Abstract] [Full Text] [Related]
26. Inter-organ Communication Pathway Manifested by Non-physiological Stress to the Kidney in Type II Diabetic Patients -Why Are Diabetic Patients Prone to Develop Heart Failure?
Sano M
Intern Med; 2020 Jan; 59(1):1-5. PubMed ID: 31178515
[TBL] [Abstract][Full Text] [Related]
27. A new era of diabetic kidney disease treatment with sodium-glucose cotransporter-2 inhibitors.
Kume S; Maegawa H
J Diabetes Investig; 2022 May; 13(5):765-767. PubMed ID: 35029051
[TBL] [Abstract][Full Text] [Related]
28. A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors.
Sen T; Heerspink HJL
Cell Metab; 2021 Apr; 33(4):732-739. PubMed ID: 33691091
[TBL] [Abstract][Full Text] [Related]
29. Failure to confirm a sodium-glucose cotransporter 2 inhibitor-induced hematopoietic effect in non-diabetic rats with renal anemia.
Yamazaki D; Konishi Y; Morikawa T; Kobara H; Masaki T; Hitomi H; Osafune K; Nakano D; Kittikulsuth W; Nishiyama A
J Diabetes Investig; 2020 Jul; 11(4):834-843. PubMed ID: 31880858
[TBL] [Abstract][Full Text] [Related]
30. Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure.
Scheen AJ
Curr Cardiol Rep; 2019 Jun; 21(8):70. PubMed ID: 31227915
[TBL] [Abstract][Full Text] [Related]
31. More CREDENCE for SGLT2 Inhibition.
Verma S; Bhatt DL
Circulation; 2019 Oct; 140(18):1448-1450. PubMed ID: 31181959
[No Abstract] [Full Text] [Related]
32. Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review.
Zelniker TA; Braunwald E
J Am Coll Cardiol; 2020 Feb; 75(4):435-447. PubMed ID: 32000956
[TBL] [Abstract][Full Text] [Related]
33. A Potential Mechanism of Cardio-Renal Protection with Sodium-Glucose Cotransporter 2 Inhibitors: Amelioration of Renal Congestion.
Kuriyama S
Kidney Blood Press Res; 2019; 44(4):449-456. PubMed ID: 31291624
[TBL] [Abstract][Full Text] [Related]
34. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
[TBL] [Abstract][Full Text] [Related]
35. SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
[TBL] [Abstract][Full Text] [Related]
36. Effect of sodium-glucose cotransporter-2 inhibitors on renal handling of electrolytes.
Meena P; Bhargava V; Bhalla A; Rana D; Mantri A
Postgrad Med J; 2021 Dec; 97(1154):819-824. PubMed ID: 33563713
[TBL] [Abstract][Full Text] [Related]
37. Lessons from the Trials for the Desirable Effects of Sodium Glucose Co-Transporter 2 Inhibitors on Diabetic Cardiovascular Events and Renal Dysfunction.
Wakisaka M; Kamouchi M; Kitazono T
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31726765
[TBL] [Abstract][Full Text] [Related]
38. Do four SGLT2 inhibitors lead to different cardiorenal benefits in type 2 diabetes, in chronic heart failure, and in chronic kidney disease?
Qiu M; Ding LL; Zhan ZL; Zhou HR
Eur J Intern Med; 2021 May; 87():98-99. PubMed ID: 33485738
[No Abstract] [Full Text] [Related]
39. Sodium-glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease.
Stavropoulos K; Imprialos KP; Stavropoulos N; Bouloukou S; Kerpiniotis G; Dimitriadis K; Tsioufis C; Doumas M
Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):120-126. PubMed ID: 29412122
[TBL] [Abstract][Full Text] [Related]
40. Research digest: SGLT2 inhibition in kidney and liver disease.
Preiss D; Sattar N
Lancet Diabetes Endocrinol; 2019 Jun; 7(6):427. PubMed ID: 31103176
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]